-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎WuXi AppTec content team editor
Under the agreement, Tavros will receive an upfront payment of $17.
5 million from Vividion and approximately $430 million based on subsequent preclinical, clinical and commercial development milestones
.
Vividion's parent company, Bayer, also has the right to choose up to 5 additional targets on top of this partnership, which may bring up to about 480 million to
Tavros.
"The future of cancer treatment lies in the use of precision targeted therapies
in an ideal clinical setting.
This collaboration enables Tavros to expand our platform into new target areas, as a result of combining our precision cancer platform with Vividion's superior targeted non-druggable platform," said Dr.
Eoin McDonnell, co-founder and CEO of Tavros.
By combining the expertise of both companies, we will discover and drug the next generation of high-value targets while increasing the potency
of potential candidate compounds.
"
WuXi AppTec provides integrated, end-to-end new drug development and manufacturing services to the global biopharmaceutical industry, covering chemical drug development and manufacturing, biological research, preclinical testing and clinical trial development, cell and gene therapy development, testing and manufacturing
.
If you have related business needs, please click the picture below to fill in the specific information
.
Vividion Therapeutics, a Bayer unit, and Tavros Therapeutics jointly announced a strategic collaboration agreement to jointly discover or target four oncology targets over the first 5 years
.
Under the agreement, Tavros could receive up to $930 million in funding
.
Tavros is a company
that develops precision cancer treatments by targeting cancer genetic vulnerability.
The company's modular, fast-to-scale, next-generation bi-directional synthetic lethality platform enables precise and direct identification of genetic interactions to enable the discovery of breakthrough targets for the development of "first-in-class" cancer drugs
.
Advanced functional genomics and in sit-out analysis can accelerate this target search process
.
Vividion is a company
that uses innovative discovery technologies to unlock high-value, traditionally undruggable targets, and treat cancer and immune disorders through precision therapies.
Vividion's platform can identify hundreds of previously unknown functional "pockets" that are present in validated protein targets in
many diseases.
At the same time, through the company's proprietary covalent chemistry library, highly selective complexes targeting these "pockets" can be identified as drug
candidates.
Vividion, through its proprietary chemical proteomics platform, is able to advance the development of different pipelines to target high-value, non-druggable targets in cancer and immunology
.
Related reading: Express | $2 billion to help target "undruggable" targets, Bayer acquires star companies
Under the agreement, Tavros will receive an upfront payment of $17.
5 million from Vividion and approximately $430 million based on subsequent preclinical, clinical and commercial development milestones
.
Vividion's parent company, Bayer, also has the right to choose up to 5 additional targets on top of this partnership, which may bring up to about 480 million to
Tavros.
"The future of cancer treatment lies in the use of precision targeted therapies
in an ideal clinical setting.
This collaboration enables Tavros to expand our platform into new target areas, as a result of combining our precision cancer platform with Vividion's superior targeted non-druggable platform," said Dr.
Eoin McDonnell, co-founder and CEO of Tavros.
By combining the expertise of both companies, we will discover and drug the next generation of high-value targets while increasing the potency
of potential candidate compounds.
"
WuXi AppTec provides integrated, end-to-end new drug development and manufacturing services to the global biopharmaceutical industry, covering chemical drug development and manufacturing, biological research, preclinical testing and clinical trial development, cell and gene therapy development, testing and manufacturing
.
If you have related business needs, please click the picture below to fill in the specific information
.
Resources:
[1] Tavros Therapeutics and Vividion Therapeutics Announce Strategic Collaboration to Discover and Enhance Targeted Oncology Programs.
Retrieved October 12, 2022 from style="margin-bottom: 0px;line-height: normal;">[2] Bayer's Vividion Bets up to $930M for Tavros Oncology Partnership.
Retrieved October 12, 2022 from style="margin-bottom: 0px;line-height: normal;">
Disclaimer: WuXi AppTec's content team focuses on global biomedical health research progress
.
This article is for information exchange purposes only, and the views expressed in this article do not represent WuXi AppTec's position, nor do they represent WuXi AppTec's support or opposition to the views
in this article.
This article is also not a treatment recommendation
.
For guidance on treatment options, go to a regular hospital
.
